<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="ja">
	<id>https://bsd.neuroinf.jp/w/index.php?action=history&amp;feed=atom&amp;title=Equilin</id>
	<title>Equilin - 版の履歴</title>
	<link rel="self" type="application/atom+xml" href="https://bsd.neuroinf.jp/w/index.php?action=history&amp;feed=atom&amp;title=Equilin"/>
	<link rel="alternate" type="text/html" href="https://bsd.neuroinf.jp/w/index.php?title=Equilin&amp;action=history"/>
	<updated>2026-04-12T10:52:20Z</updated>
	<subtitle>このウィキのこのページに関する変更履歴</subtitle>
	<generator>MediaWiki 1.43.8</generator>
	<entry>
		<id>https://bsd.neuroinf.jp/w/index.php?title=Equilin&amp;diff=49804&amp;oldid=prev</id>
		<title>WikiSysop: 1版 をインポートしました</title>
		<link rel="alternate" type="text/html" href="https://bsd.neuroinf.jp/w/index.php?title=Equilin&amp;diff=49804&amp;oldid=prev"/>
		<updated>2025-03-18T10:29:13Z</updated>

		<summary type="html">&lt;p&gt;1版 をインポートしました&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;ja&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← 古い版&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;2025年3月18日 (火) 19:29時点における版&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;4&quot; class=&quot;diff-notice&quot; lang=&quot;ja&quot;&gt;&lt;div class=&quot;mw-diff-empty&quot;&gt;(相違点なし)&lt;/div&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;!-- diff cache key wiki-mw_:diff:1.41:old-49803:rev-49804 --&gt;
&lt;/table&gt;</summary>
		<author><name>WikiSysop</name></author>
	</entry>
	<entry>
		<id>https://bsd.neuroinf.jp/w/index.php?title=Equilin&amp;diff=49803&amp;oldid=prev</id>
		<title>bsd&gt;JWBE: removed Category:Phenols; added Category:Hydroxyarenes using HotCat</title>
		<link rel="alternate" type="text/html" href="https://bsd.neuroinf.jp/w/index.php?title=Equilin&amp;diff=49803&amp;oldid=prev"/>
		<updated>2024-10-21T11:59:46Z</updated>

		<summary type="html">&lt;p&gt;removed &lt;a href=&quot;/w/index.php?title=%E3%82%AB%E3%83%86%E3%82%B4%E3%83%AA:Phenols&amp;amp;action=edit&amp;amp;redlink=1&quot; class=&quot;new&quot; title=&quot;カテゴリ:Phenols (存在しないページ)&quot;&gt;Category:Phenols&lt;/a&gt;; added &lt;a href=&quot;/w/index.php?title=%E3%82%AB%E3%83%86%E3%82%B4%E3%83%AA:Hydroxyarenes&amp;amp;action=edit&amp;amp;redlink=1&quot; class=&quot;new&quot; title=&quot;カテゴリ:Hydroxyarenes (存在しないページ)&quot;&gt;Category:Hydroxyarenes&lt;/a&gt; using &lt;a href=&quot;/w/index.php?title=WP:HC&amp;amp;action=edit&amp;amp;redlink=1&quot; class=&quot;new&quot; title=&quot;WP:HC (存在しないページ)&quot;&gt;HotCat&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;新規ページ&lt;/b&gt;&lt;/p&gt;&lt;div&gt;{{Short description|Chemical compound}}&lt;br /&gt;
{{Distinguish|Equilenin}}&lt;br /&gt;
{{Drugbox&lt;br /&gt;
| Verifiedfields = verified&lt;br /&gt;
| Watchedfields = verified&lt;br /&gt;
| verifiedrevid = 461094587&lt;br /&gt;
| IUPAC_name = (9&amp;#039;&amp;#039;S&amp;#039;&amp;#039;,13&amp;#039;&amp;#039;S&amp;#039;&amp;#039;,14&amp;#039;&amp;#039;S&amp;#039;&amp;#039;)-3-hydroxy-13-methyl-9,11,12,14,15,16-hexahydro-6&amp;#039;&amp;#039;H&amp;#039;&amp;#039;-cyclopenta[&amp;#039;&amp;#039;a&amp;#039;&amp;#039;]phenanthren-17-one&lt;br /&gt;
| image = Equilin.svg&lt;br /&gt;
| width = 225px&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--Clinical data--&amp;gt;&lt;br /&gt;
| tradename =&lt;br /&gt;
| pregnancy_AU = &amp;lt;!-- A / B1 / B2 / B3 / C / D / X --&amp;gt;&lt;br /&gt;
| pregnancy_US = &amp;lt;!-- A / B / C / D / X --&amp;gt;&lt;br /&gt;
| pregnancy_category =&lt;br /&gt;
| legal_AU = &amp;lt;!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --&amp;gt;&lt;br /&gt;
| legal_CA =&lt;br /&gt;
| legal_UK =&lt;br /&gt;
| legal_US =&lt;br /&gt;
| legal_status =&lt;br /&gt;
| routes_of_administration = [[Oral administration|By mouth]]&lt;br /&gt;
| class = [[Estrogen (medication)|Estrogen]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--Pharmacokinetic data--&amp;gt;&lt;br /&gt;
| bioavailability =&lt;br /&gt;
| protein_bound =&lt;br /&gt;
| metabolism =&lt;br /&gt;
| elimination_half-life =&lt;br /&gt;
| excretion =&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--Identifiers--&amp;gt;&lt;br /&gt;
| CAS_number_Ref = {{cascite|correct|CAS}}&lt;br /&gt;
| CAS_number = 474-86-2&lt;br /&gt;
| CAS_supplemental =&lt;br /&gt;
| ATC_prefix =&lt;br /&gt;
| ATC_suffix =&lt;br /&gt;
| ATC_supplemental =&lt;br /&gt;
| PubChem = 223368&lt;br /&gt;
| IUPHAR_ligand =&lt;br /&gt;
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}&lt;br /&gt;
| DrugBank = DB02187&lt;br /&gt;
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}&lt;br /&gt;
| ChemSpiderID = 193995&lt;br /&gt;
| UNII_Ref = {{fdacite|correct|FDA}}&lt;br /&gt;
| UNII = 08O86EX0J4&lt;br /&gt;
| KEGG_Ref = {{keggcite|correct|kegg}}&lt;br /&gt;
| KEGG = D04041&lt;br /&gt;
| ChEBI_Ref = {{ebicite|correct|EBI}}&lt;br /&gt;
| ChEBI = 42309&lt;br /&gt;
| ChEMBL_Ref = {{ebicite|correct|EBI}}&lt;br /&gt;
| ChEMBL = 323533&lt;br /&gt;
| synonyms = Δ&amp;lt;sup&amp;gt;7&amp;lt;/sup&amp;gt;-Estrone; 7-Dehydroestrone; Estra-1,3,5(10),7-tetraen-3-ol-17-one&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--Chemical data--&amp;gt;&lt;br /&gt;
| C=18 | H=20 | O=2&lt;br /&gt;
| SMILES = O=C3CC[C@H]4C/2=C/Cc1c(ccc(O)c1)[C@H]\2CC[C@]34C&lt;br /&gt;
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}&lt;br /&gt;
| StdInChI = 1S/C18H20O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3-5,10,14,16,19H,2,6-9H2,1H3/t14-,16+,18+/m1/s1&lt;br /&gt;
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}&lt;br /&gt;
| StdInChIKey = WKRLQDKEXYKHJB-HFTRVMKXSA-N&lt;br /&gt;
}}&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Equilin&amp;#039;&amp;#039;&amp;#039; is a [[natural product|naturally occurring]] [[estrogen (medication)|estrogen]] [[sex hormone]] found in [[horse]]s as well as a [[medication]].&amp;lt;ref name=&amp;quot;Elks2014&amp;quot;&amp;gt;{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&amp;amp;pg=PA298|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|page=495}}&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot;&amp;gt;{{cite journal | vauthors = Kuhl H | title = Pharmacology of estrogens and progestogens: influence of different routes of administration | journal = Climacteric | volume = 8 | pages = 3–63 | year = 2005 | issue = Suppl 1 | pmid = 16112947 | doi = 10.1080/13697130500148875 | s2cid = 24616324 | url = http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf}}&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;pmid24176763&amp;quot;&amp;gt;{{cite journal | vauthors = Bhavnani BR, Stanczyk FZ | title = Pharmacology of conjugated equine estrogens: efficacy, safety and mechanism of action | journal = J. Steroid Biochem. Mol. Biol. | volume = 142 | pages = 16–29 | date = July 2014 | pmid = 24176763 | doi = 10.1016/j.jsbmb.2013.10.011 | s2cid = 1360563 }}&amp;lt;/ref&amp;gt; It is one of the estrogens present in the estrogen [[combination drug]] preparations known as [[conjugated estrogens]] (CEEs; e.g. &amp;#039;&amp;#039;&amp;#039;Premarin&amp;#039;&amp;#039;&amp;#039;) and [[esterified estrogens]] (EEs; e.g. &amp;#039;&amp;#039;&amp;#039;Estratab&amp;#039;&amp;#039;&amp;#039;, &amp;#039;&amp;#039;&amp;#039;Menest&amp;#039;&amp;#039;&amp;#039;).&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;pmid24176763&amp;quot; /&amp;gt; CEEs is the most commonly used form of estrogen medications in [[hormone replacement therapy]] (HRT) for [[menopausal symptoms]] in the [[United States]].&amp;lt;ref name=&amp;quot;pmid24176763&amp;quot; /&amp;gt; [[Estrone sulfate (medication)|Estrone sulfate]] is the major estrogen in CEEs (about 50%) while equilin sulfate is the second major estrogen in the formulation, present as about 25% of the total.&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;pmid24176763&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pharmacology==&lt;br /&gt;
&lt;br /&gt;
===Pharmacodynamics===&lt;br /&gt;
Equilin is an estrogen, or an [[agonist]] of the [[estrogen receptor]]s (ERs), the [[ERα]] and [[ERβ]].&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot; /&amp;gt; In terms of [[relative binding affinity]] for the ERs, equilin has about 13% and 49% of that of estradiol for the ERα and ERβ, respectively.&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot; /&amp;gt; Analogously to the reversible transformation of [[estrone (medication)|estrone]] into [[estradiol (medication)|estradiol]] by [[17β-hydroxysteroid dehydrogenase]], equilin can be converted into the more potent estrogen [[17β-dihydroequilin]] in the body.&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;pmid24176763&amp;quot; /&amp;gt; This estrogen has about 113% and 108% of the relative binding affinities of estradiol for the ERα and ERβ, respectively.&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;pmid24176763&amp;quot; /&amp;gt; Equilin is present in CEEs in the form of equilin sulfate, which itself is inactive and acts as a [[prodrug]] of equilin via [[steroid sulfatase]].&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;pmid24176763&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Similarly to [[synthetic compound|synthetic]] estrogens like [[ethinylestradiol]], equilin and CEEs have disproportionate effects in certain [[tissue (biology)|tissue]]s such as the [[liver]] and [[uterus]] relative to [[bioidentical]] human estrogens like estradiol and estrone.&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot; /&amp;gt; Because of their disproportionate potency in the liver, equilin and CEEs have relatively increased effects on [[liver protein synthesis]] compared to estradiol.&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A dosage of 0.25&amp;amp;nbsp;mg/day equilin sulfate is equivalent to 0.625&amp;amp;nbsp;mg/day CEEs in terms of relief from [[hot flash]]es.&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot; /&amp;gt; At a dosage of 0.625&amp;amp;nbsp;mg/day equilin sulfate, the increases in circulating levels of [[sex hormone-binding globulin]] (SHBG), [[corticosteroid-binding globulin]], and [[angiotensinogen]] were 1.5 to 8&amp;amp;nbsp;times those observed with [[estrone sulfate (medication)|estrone sulfate]].&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot; /&amp;gt; Equilin has about 42% of the relative potency of CEEs in the [[vagina]] and 80% of the relative potency of CEEs in the [[uterus]], while its more active form, 17β-dihydroequilin, has about 83% of the relative potency of CEEs in the vagina and 200% of the relative potency of CEEs in the uterus.&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{{Relative oral potencies of estrogens}}&lt;br /&gt;
&lt;br /&gt;
===Pharmacokinetics===&lt;br /&gt;
Equilin has about 8% of the [[relative binding affinity]] of [[testosterone]] for SHBG, relative to 12% in the case of [[estrone (medication)|estrone]].&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot; /&amp;gt; In terms of [[plasma protein binding]], it is bound 26% to SHBG and 13% to [[human serum albumin|albumin]].&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot; /&amp;gt; The [[metabolic clearance rate]]s of equilin and equilin sulfate are 2,640&amp;amp;nbsp;L/day/m&amp;lt;sup&amp;gt;2&amp;lt;/sup&amp;gt; and 175&amp;amp;nbsp;L/day/m&amp;lt;sup&amp;gt;2&amp;lt;/sup&amp;gt;, respectively.&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot; /&amp;gt; In accordance, the [[biological half-life]] of equilin sulfate is substantially longer than that of equilin.&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot; /&amp;gt; Equilin is converted into [[17β-dihydroequilin]] in the [[liver]] and in other [[tissue (biology)|tissue]]s.&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;pmid24176763&amp;quot; /&amp;gt; Equilin and 17β-dihydroequilin can also be transformed into [[equilenin]] and [[17β-dihydroequilenin]].&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;pmid24176763&amp;quot; /&amp;gt; Equilin is [[excretion|excreted]] in the form of [[glucuronide]] conjugates.&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Chemistry==&lt;br /&gt;
{{See also|List of estrogens#Equine estrogens}}&lt;br /&gt;
&lt;br /&gt;
Equilin, also known as δ&amp;lt;sup&amp;gt;7&amp;lt;/sup&amp;gt;-estrone or as 7-dehydroestrone, as well as estra-1,3,5(10),7-tetraen-3-ol-17-one, is a [[natural product|naturally occurring]] [[estrane]] [[steroid]] and an [[structural analog|analogue]] of [[estrone (medication)|estrone]].&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;pmid24176763&amp;quot; /&amp;gt; In terms of [[chemical structure]] and [[pharmacology]], equilin is to [[17β-dihydroequilin]] (δ&amp;lt;sup&amp;gt;7&amp;lt;/sup&amp;gt;-17β-estradiol) as estrone is to [[estradiol (medication)|estradiol]].&amp;lt;ref name=&amp;quot;pmid16112947&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;pmid24176763&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
{{Reflist}}&lt;br /&gt;
&lt;br /&gt;
{{Estrogens and antiestrogens}}&lt;br /&gt;
{{Estrogen receptor modulators}}&lt;br /&gt;
&lt;br /&gt;
[[Category:Sterols]]&lt;br /&gt;
[[Category:Hydroxyarenes]]&lt;br /&gt;
[[Category:Estranes]]&lt;br /&gt;
[[Category:Estrogens]]&lt;br /&gt;
[[Category:Human drug metabolites]]&lt;br /&gt;
[[Category:Ketones]]&lt;br /&gt;
[[Category:Prodrugs]]&lt;/div&gt;</summary>
		<author><name>bsd&gt;JWBE</name></author>
	</entry>
</feed>